Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
No genetic correlation was seen with Merck & Co's CETP inhibitor, but Dalcor believes that things will be different for dalcetrapib.
As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
Dermira hopes that lebrikizumab can beat Dupixent, while Conatus tries to overcome an earlier Nash setback.
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
The UK ortho and woundcare group might yet pounce on Nuvasive.